RemeOs is an MRI-compatible, absorbable hybrid composite and is designed for cervical spinal fusion, the company said in an Oct. 4 news release.
The company’s financial targets were also upgraded in light of the decision to accelerate RemeOs development. Bioretec increased its net sales forecast to more than $71 million by the end of 2028 and expects to see positive operational cash flow by the end of 2027 instead of 2026.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
